npr.org
This drug is a true gamechanger
In the SURMOUNT-1 study, people who took the highest dose of tirzepatide, most of whom had a BMI of about 30 or higher but did not have diabetes, lost about 21% of their body weight during the 72 week study. As researchers point out, for people who have bariatric surgery, typical weight loss is about 25% to 30% of their weight, one or two years after the surgery. In the tirzepatide study, 36% of people taking the highest dose lost 25% or more of their body weight.
this is comparable to bariatric surgery
Jump in the discussion.
No email address required.
Notes -
It'll be absolutely fascinating to see the social changes that accompany a family of drugs that make obesity, if not optional, then at least curable. Particularly if national health services subsidize these drugs to make them affordable.
I'm envisioning a situation where a GLP-1 agonist prescription is as normal as eyeglasses for the middle aged. Obese people could become as unusual a sight as they were a century ago.
More options
Context Copy link